Mode
Text Size
Log in / Sign up

Earlier salivary melatonin onset associated with respiratory symptoms in early amyotrophic lateral sclerosisSleep Timing Could Predict Survival in Early ALS

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider DLMO timing as a potential non-invasive prognostic biomarker for respiratory symptoms in early amyotrophic lateral sclerosis.

This prospective longitudinal observational study examined salivary dim-light melatonin onset (DLMO) in 50 people living with amyotrophic lateral sclerosis (plwALS) and age and sex matched controls. The study focused on early disease within 18 months of symptom onset using home-based sampling protocols. Participants were enrolled to assess prognostic information for functional decline, respiratory symptom emergence, and survival.

PlwALS demonstrated an earlier DLMO compared to controls, with timing recorded at 20:24 versus 20:58 (p=0.028). In the 6-month follow-up (T6), later baseline DLMO correlated with incident dyspnea or orthopnea (adjusted OR 3.02, p=0.017). A re-sampled subgroup of 28 participants showed no change in DLMO metrics over the 6-month period. Secondary outcomes assessed functional motor status, disease progression, and tracheostomy-free outcome.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The authors note that endogenous circadian phase timing and its prognostic significance in early disease remain unclear. Limitations include the need for validation in larger multicentre cohorts. DLMO may represent a non-invasive prognostic biomarker for progression, though causality was not established.

Imagine waking up feeling tired even after a full night's rest. For people with ALS, sleep problems are common but often misunderstood.

New research suggests sleep timing predicts how fast ALS gets worse and who survives longer without extra help.

This finding offers a new way to understand the disease before symptoms get severe.

Sleep Timing Links to ALS Survival

Doctors have long noticed that people with ALS struggle with sleep. They often wake up too early or feel exhausted during the day.

But this study looked deeper than just how much sleep they got. It measured the exact time their bodies released melatonin.

Melatonin is a hormone that tells your brain when to sleep. Think of it like a biological alarm clock.

The study found that the timing of this alarm clock matters for survival.

Why Melatonin Matters for Patients

ALS attacks the nerves that control movement and breathing. It is a fast-moving disease that changes lives quickly.

Doctors need better tools to know who might get worse sooner. This helps them plan care and support earlier.

Sleep timing might be that tool. It is easy to measure and does not require surgery.

The study showed that melatonin timing changed in people with early ALS.

The Study Behind the Findings

Researchers followed fifty people who had just been diagnosed with ALS. They collected saliva samples at home during the night.

They compared these results to healthy people of the same age and sex. The goal was to see if the disease changed the body clock.

The team tracked these patients for six months to see how their health changed.

They also looked at who needed breathing help or a tracheostomy.

The Catch With This New Test

The results showed a clear link between melatonin timing and disease speed. People with later melatonin onset had worse outcomes.

This means the body clock shift is not just a side effect. It might be a sign of how aggressive the disease is.

This doesn't mean this treatment is available yet.

Doctors cannot change your sleep timing to cure ALS right now. But they can use this to monitor your health better.

What Happens Next for Research

This study is a first step in a larger journey. It needs to be tested in bigger groups of people.

Researchers want to see if this works across different hospitals and countries. They also need to check if the timing stays the same over time.

If it holds up, doctors might use this test to guide treatment plans.

It could help families prepare for the future sooner.

The science is moving fast, but patience is still needed. Real-world use depends on more data.

For now, the focus remains on managing symptoms and quality of life.

Sleep remains a vital part of health for everyone.

This new insight adds another piece to the puzzle of ALS care.

Patients should talk to their doctors about sleep issues. They might offer new ways to track progress.

The road ahead is long, but the path is clearer now.

Study Details

Study typeCohort
Sample sizen = 28
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Sleep wake and circadian disturbances are increasingly recognised in people living with amyotrophic lateral sclerosis (plwALS), but endogenous circadian phase timing and its prognostic significance in early disease remain unclear. We assessed whether salivary dim-light melatonin onset (DLMO), an objective marker of central circadian phase, is altered in early plwALS and whether it provides prognostic information. Methods: In this prospective longitudinal observational study, plwALS within 18 months of symptom onset underwent home-based salivary melatonin sampling under dim light conditions at six predefined time points around habitual sleep onset (HSO). Melatonin profiles were modeled using cubic smoothing splines, and DLMO was defined as the first time the fitted curve reached 3 pg/mL. Clinical, respiratory, and sleep assessments were collected at baseline (T0) and after 6 months (T6); a subgroup repeated saliva sampling at T6. Age and sex matched controls underwent melatonin profiling. Associations with disease progression, incident respiratory symptoms, and survival/tracheostomy were examined using regressions and survival analyses. Results: Fifty plwALS were enrolled. Compared with controls, plwALS showed an earlier DLMO (20:24 vs 20:58; p=0.028) despite similar HSO and chronotype. Within ALS cohort, a later baseline DLMO correlated with worse functional/motor status, faster progression of disease, incident dyspnea/orthopnea by T6 (adjusted OR 3.02; p=0.017), and poorer survival/tracheostomy-free outcome. In re-sampled subgroup (n=28), DLMO and other melatonin-derived metrics did not change over 6 months. Conclusions: Circadian phase alterations are detectable in early ALS. Baseline DLMO may represent a non-invasive prognostic biomarker for progression, respiratory symptom emergence and survival, warranting validation in larger multicentre cohorts.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.